Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

The cost-efficient model dubbed Gemini 2.0 Flash-Lite comes as a successor to the Gemini 1.5 Flash while sticking to the same ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex’s drug works in a completely different way ... Lidocaine, a local anesthetic, works by blocking all sodium channels in ...

Example 1: Here is a VNF where the top face is missing. It is not a valid polyhedron like this, but we can use it as a building block to make a polyhedron. include <BOSL2/std.scad> bottom = vnf_vertex ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Vertex valuation multiples have reached unsustainable heights at ~11x forward revenue, which increases its risk for a correction. Vertex specializes in corporate tax compliance software, targeting ...